ADC THERAPEUTICS SA's ticker is ADCT and the CUSIP is H0036K147. A total of 68 filers reported holding ADC THERAPEUTICS SA in Q3 2022. The put-call ratio across all filers is 2.81 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $763,111 | -59.9% | 850,737 | -3.9% | 0.51% | -53.2% |
| Q2 2023 | $1,903,868 | -17.7% | 885,520 | -25.3% | 1.10% | -16.6% |
| Q1 2023 | $2,313,119 | -49.2% | 1,186,215 | 0.0% | 1.31% | -51.2% |
| Q4 2022 | $4,555,066 | -20.3% | 1,186,215 | 0.0% | 2.69% | -19.5% |
| Q3 2022 | $5,718,000 | -39.4% | 1,186,215 | 0.0% | 3.34% | -36.8% |
| Q2 2022 | $9,430,000 | -61.8% | 1,186,215 | -29.4% | 5.29% | -45.1% |
| Q1 2022 | $24,681,000 | -27.3% | 1,680,149 | 0.0% | 9.63% | +5.5% |
| Q4 2021 | $33,939,000 | -25.6% | 1,680,149 | 0.0% | 9.12% | -6.6% |
| Q3 2021 | $45,633,000 | +11.5% | 1,680,149 | 0.0% | 9.77% | +37.3% |
| Q2 2021 | $40,911,000 | -0.2% | 1,680,149 | 0.0% | 7.12% | -13.6% |
| Q1 2021 | $41,012,000 | -23.7% | 1,680,149 | 0.0% | 8.23% | +88.0% |
| Q4 2020 | $53,782,000 | – | 1,680,149 | – | 4.38% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vantage Consulting Group Inc | 1,186,215 | $5,718,000 | 3.34% |
| Blue Owl Capital Holdings LP | 733,568 | $3,536,000 | 1.53% |
| Redmile Group, LLC | 7,512,029 | $36,208,000 | 1.40% |
| GCM Grosvenor Holdings, LLC | 735,471 | $3,545,000 | 0.84% |
| Prosight Management, LP | 247,630 | $1,194,000 | 0.64% |
| Indie Asset Partners, LLC | 93,839 | $452,000 | 0.46% |
| MPM BioImpact LLC | 334,384 | $1,612,000 | 0.38% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,390,297 | $11,521,000 | 0.23% |
| Eventide Asset Management | 1,879,959 | $9,061,000 | 0.18% |
| APOGEM CAPITAL LLC | 17,405 | $84,000 | 0.08% |